Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial.
Background. Breast cancer patients receiving adjuvant chemotherapy often experience a loss of quality of life. Moreover chemotherapy may induce neutropenia. Patients report a better quality of life when additionally treated with mistletoe products during chemotherapy. Methods. In this prospective randomized open-label pilot study 95 patients were randomized into three groups. All patients were treated with an adjuvant chemotherapy. The primary objective of the study was quality of life, the secondary objective was neutropenia. Here we report the comparison of HxA (n = 34) versus untreated control (n = 31). Results. In the explorative analysis ten of 15 scores of the EORTC QLQ-C30 showed a better quality of life in the HxA group compared to the control group (P < 0.001 to P = 0.038 in Dunnett-T3 test). The difference was clinically relevant (difference of at least 5 points, range 5.4-12.2) in eight of the ten scores. Neutropenia occurred in 7/34 HxA patients and in 8/31 control patients (P = 0.628). Conclusions. This pilot study showed an improvement of quality of life by treating breast cancer patients with HxA additionally to CAF. Although the open design may be a limitation, the findings show the feasibility of a confirmatory study using the methods described here.
Clinical Research Dr. Tröger, Zechenweg 6, 79111 Freiburg, Germany.
Wilfried
W
Tröger
Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
Zdravko
Z
Zdrale
Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
Nevena
N
Tišma
Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
Miodrag
M
Matijašević